BMS-986368
Sponsors
Celgene
Conditions
AgitationAlzheimer DiseaseHealthy ParticipantsHealthy VolunteersMultiple Sclerosis Spasticity
Phase 1
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants
CompletedNCT06170723
Start: 2024-03-18End: 2024-05-25Updated: 2024-07-01
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity
CompletedNCT06411730
Start: 2024-05-31End: 2024-10-28Updated: 2024-11-12
A Study to Evaluate the Blood Levels, Safety, and Tolerability of BMS-986368 in Healthy Chinese Participants
Not yet recruitingNCT07700329
Start: 2027-01-05End: 2027-02-23Target: 16Updated: 2026-07-14
Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
RecruitingNCT06782490
Start: 2025-06-05End: 2027-06-09Target: 200Updated: 2026-09-09
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
RecruitingNCT06808984
Start: 2025-06-09End: 2028-01-07Target: 120Updated: 2026-09-01